The brown lacewings (Neuroptera, Hemerobiidae) of northwestern Turkey with new records, their spatio-temporal distribution and harbouring plants

The brown lacewings (Neuroptera, Hemerobiidae) of northwestern Turkey with new records, their spatio-temporal distribution and harbouring plants. The occurrence and spatio-temporal distribution of brown lacewing species (Neuroptera, Hemerobiidae) in Bursa province, northwestern Turkey, was investigated during 1999-2011. A total of 852 brown lacewing specimens of 20 species, including the genera of Hemerobius, Megalomus, Micromus, Sympherobius, and Wesmaelius were collected. Of these, 12 species were new records for northwestern Turkey while Sympherobius klapaleki is a new record for the Neuroptera fauna of Turkey. The most widespread species were Hemerobius handschini and Sympherobius pygmaeus with percent dominance values of 42.00 and 15.96%, respectively. Wesmaelius subnebulosus was the earliest emerging hemerobiid species and had the longest flight activity lasting from March to October. The species of southern origin characterized by the Mediterranean elements constituted 55% of the hemerobiid fauna and prevailed over the species of northern origin that belong to the Siberian centres. The total number of hemerobiid species reached a peak in July with captures of 15 species per month. There were 11, 13, 18 and 5 hemerobiid species occurring at altitudes between 1-500, 501-1000, 1001-1500 and 1500-2000 m, respectively. In addition, plant species harbouring hemerobiids are given for each species, and their association with the hemerobiid fauna is discussed.

Venous cannula performance assessment in a realistic caval tree model.

OBJECTIVES: A new caval tree system was designed for realistic in vitro simulation. The objective of our study was to assess cannula performance for virtually wall-less versus standard percutaneous thin-walled venous cannulas in a setting of venous collapse in case of negative pressure. METHODS: For a collapsible caval model, a very flexible plastic material was selected, and a model with nine afferent veins was designed according to the anatomy of the vena cava. A flow bench was built including a lower reservoir holding the caval tree, built by taking into account the main afferent vessels and their flow provided by a reservoir 6 cm above. A cannula was inserted in this caval tree and connected to a centrifugal pump that, in turn, was connected to a reservoir positioned 83 cm above the second lower reservoir (after-load = 60 mmHg). Using the same pre-load, the simulated venous drainage for cardiopulmonary bypass was realized using a 24 F wall-less cannula (Smartcanula) and 25 F percutaneous cannula (Biomedicus), and stepwise increased augmentation (1500 RPM, 2000 and 2500 RPM) of venous drainage. RESULTS: For the thin wall and the wall-less cannulas, 36 pairs of flow and pressure measurements were realized for three different RPM values. The mean Q-values at 1500, 2000 and 2500 RPM were: 3.98 ± 0.01, 6.27 ± 0.02 and 9.81 ± 0.02 l/min for the wall-less cannula (P <0.0001), versus 2.74 ± 0.02, 3.06 ± 0.05, 6.78 ± 0.02 l/min for the thin-wall cannula (P <0.0001). The corresponding inlet pressure values were: -8.88 ± 0.01, -23.69 ± 0.81 and -70.22 ± 0.18 mmHg for the wall-less cannula (P <0.0001), versus -36.69 ± 1.88, -80.85 ± 1.71 and -101.83 ± 0.45 mmHg for the thin-wall cannula (P <0.0001). The thin-wall cannula showed mean Q-values 37% less and mean P values 26% more when compared with the wall-less cannula (P <0.0001). CONCLUSIONS: Our in vitro water test was able to mimic a negative pressure situation, where the wall-less cannula design performs better compared with the traditional thin-wall cannula.

« L'Art de rethorique », par « maistre JEHAN MOLINET ».

Commençant par : « Pour ce que nouvellement, comme j'entens par voz gracieuses missives, estes tiré soubz l'estandart de Cupido... » et finissant par : «... ja masse, (massa); je Masse (mulier) » .

Sermons pour différentes fêtes de l'année.

Début : « Convertimini ad me in toto corde vestro, Johelis secundo capitulo. Le saint prophete Johel, qui est ung des XII. petis prophetes, voiant la grant tribulacion... »

Kauppias, kaupunki, kruunu : Turun porvariyhteisö ja talouden organisaatio varhaiskeskiajalta 1570-luvulle

Summary: The merchant, the town and the crown : the burgher community of Turku and economic organization from the early Middle Ages to the 1570's

Procès de condamnation et de justification de Jeanne d'Arc, précédés de la chronique du siège d'Orléans.

Abbaye de Saint-Victor de Paris

Scripta varia

Ordonnances et pièces diverses relatives au gouvernement du royaume, aux rapports de Philippe le Bel avec le Saint Siège, au grand schisme etc. F. 1, De origine singularum gentium,F. 104v, Notes sur divers événements du règne de Charles VI,F. 120, Glosa abbatis Joachim super libro Cirilli, F. 131v, Visio Johannis heremite, F. 137, Pavo, F. 140, Vincentii Ferrarii epistola de Antichristo, F. 167, Ordre de procéder en la ville et viconté de Paris, F. 194, Stilus curie parlamenti, editus per G. de Brolio, F. 255, Divers arrêts du Parlement,

« Croniques de France, extraictes des Croniques de Saint Denis en France, par Frere GUILLAUME DE NANGIS ».

Commençant par : « Pour ce que moult de gens et mesmement les haulx hommes et les nobles qui souvent viennent en l'eglise monseigneur Saint Denis de France... » et finissant par : «... couronné à Reins, le dimance IIIIe jour de novembre, l'an mil.III.C. IIII.XX, en la fin de son XIIe an » .

« Le Livre du Jardin de contemplation », par « maistre JEHAN HENRY, chantre de l'eglise de Paris ».

Commençant par : « A religieuse et devote Seur en Jhesu Crist, l'abbesse du religieux colliege des Seurs minoriques de l'ordre Saincte Clare à Esgueperse... » et finissant par : «... nous vueille donner et ottroier icellui nostre Createur qui vit et regne in secula seculorum. Amen » . En tête du volume se trouve la lettre de « l'abbesse du colliege des Seurs minoriques de Saincte Clare à Aigueperse » à Jean Henry, pour le prier de composer le Jardin de contemplation.

Biología y pesquería del perico o dorado Coryphaena hippurus, febrero 2010

La prospección para evaluar la biología y pesquería de Coryphaena hippurus perico o dorado, se efectuó del 10 de febrero al 1 de marzo 2010, a bordo del BIC Imarpe V. El área de extracción fue de 4°59’32,8’’ a 10°15’20,1’’S y de 79°55’16,2’’ a 84°35’04,2’’W; la captura total fue 1.500,5 kg. La CPUE varió de 0,9 a 18,2 kg/Nº Anzuelos/1000*hora efectiva de pesca. Se encontró alta selección interespecífi ca del espinel superfi cial, al capturar 87,8% de perico y 8 especies de peces, tortugas y cefalópodos. El rango de tallas para hembras fue 79 - 141 cm de LT, en machos fue 100 - 157 cm LT. El factor de condición de Fulton en machos varió de 0,30 a 0,46 y en hembras de 0,32 a 0,40. Se determinó para hembras: L∞=148,92 cm, tasa de crecimiento anual (K) 1,081, se estimó t0 = -0,076 años, el Índice de performance Ǿ= 4,38; para machos, estos parámetros fueron L∞=169,75 cm, tasa de crecimiento anual (K) de 0,893, t0 = -0,115, índice de performance Ǿ= 4,40. La curva de crecimiento en talla para hembras, indica que a un año de edad la LT es 102,4 cm y en machos 107 cm. El máximo crecimiento en peso para hembras y machos fue a 1,5 años de vida. El Índice gonadosomático (IGS) fl uctuó de 3,2 a 4,6 mostrando comportamiento heterogéneo. La proporción sexual fue de 2:1 favorable a las hembras. La fecundidad parcial fue de 324.416 ovocitos por tanda de desove. La fecundidad relativa fue 56 ovocitos/ gramo de peso corporal. El tipo de alimento fue peces, cefalópodos y crustáceos con dominancia de Exocoetus volitans (%IRI = 31,6), Argonauta spp. (%IRI = 26,4) mostrando variaciones según zonas y tallas. El consumo de alimento fue 472,7 g/ind./día correspondiente a 7,4% de su peso corporal, presentando fl uctuaciones con respecto a la talla; alimentándose en horas de la mañana, con un máximo entre las 8:00 y 9:59 horas. Se encontraron 5.762 parásitos, identifi cándose 8 especies en cuatro taxas. La prevalencia parasitaria indica que Tentacularia coryphaenae y Bathycotyle coryphaenae alcanzan el 100%, seguido por Hysterothylacium sp. 62% y Caligus coryphaenae 46%. El mayor número de parásitos se encontró en el estómago. Los peces entre 96–100 cm de LT son los más parasitados. La mayor incidencia parasitaria se encontró en la zona norte, en el tramo Paita-Salaverry. Los registros de temperatura en la columna de agua fueron de 12,7 a 27,3 °C y las ATSM de 0,2 a 4,1 °C. Por el frente oceánico se observaron comportamientos térmicos cálidos asociados a las masas de Aguas Ecuatoriales Superfi ciales y Aguas Subtropicales Superfi ciales y por la zona costera se localizaron Aguas Costeras Frías tanto en Chimbote como en Chicama con temperaturas próximas a 22,0 °C. La concentración de oxígeno disuelto superfi cial se presentó favorable para el perico.

Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study

Introduction: As imatinib pharmacokinetics are highly variable, plasma levels differ largely between patients under the same dosage. Retrospective studies in chronic myeloid leukemia (CML) patients showed significant correlations between low levels and suboptimal response, as well as between high levels and poor tolerability. Monitoring of trough plasma levels, targeting 1000 μg/L and above, is thus increasingly advised. Our study was launched to assess prospectively the clinical usefulness of systematic imatinib TDM in CML patients. This preliminary analysis addresses the appropriateness of the dosage adjustment approach applied in this study, which targets the recommended trough level and allows an interval of 4-24 h after last drug intake for blood sampling. Methods: Blood samples from the first 15 patients undergoing 1st TDM were obtained 1.5-25 h after last dose. Imatinib plasma levels were measured by LC-MS/MS and the concentrations were extrapolated to trough based on a Bayesian approach using a population pharmacokinetic model. Trough levels were predicted to differ significantly from the target in 12 patients (10 <750 μg/L; 2 >1500 μg/L along with poor tolerance) and individual dose adjustments were proposed. 8 patients underwent a 2nd TDM cycle. Trough levels of 1st and 2nd TDM were compared, the sample drawn 1.5 h after last dose (during distribution phase) was excluded from the analysis. Results: Individual dose adjustments were applied in 6 patients. Observed concentrations extrapolated to trough ranged from 360 to 1832 μg/L (median 725; mean 810, CV 52%) on 1st TDM and from 720 to 1187 μg/L (median 950; mean 940, CV 18%) on 2nd TDM cycle. Conclusions: These preliminary results suggest that TDM of imatinib using a Bayesian interpretation is able to target the recommended trough level of 1000 μg/L and to reduce the considerable differences in trough level exposure between patients (with CV decreasing from 52% to 18%). While this may simplify blood collection in daily practice, as samples do not have to be drawn exactly at trough, the largest possible interval to last drug intake yet remains preferable to avoid sampling during distribution phase leading to biased extrapolation. This encourages the evaluation of the clinical benefit of a routine TDM intervention in CML patients, which the randomized Swiss I-COME trial aims to.

RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.

BACKGROUND: Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for. METHODS: In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx, PEG-Dox) and prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63 patients with newly diagnosed glioblastoma. In phase-I, PEG-Dox was administered in a 3-by-3 dose-escalation regimen. In phase-II, 20 mg/m2 PEG-Dox was given once prior to radiotherapy and on days 1 and 15 of each 28-day cycle starting 4 weeks after radiotherapy. Temozolomide was given in a dose of 75 mg/m2 daily during radiotherapy (60 Gy) and 150-200 mg/m2 on days 1-5 of each 28-day cycle for 12 cycles or until disease progression. RESULTS: The toxicity of the combination of PEG-Dox, prolonged administration of Temozolomide, and radiotherapy was tolerable. The progression free survival after 12 months (PFS-12) was 30.2%, the median overall survival was 17.6 months in all patients including the ones from Phase-I. None of the endpoints differed significantly from the EORTC26981/NCIC-CE.3 data in a post-hoc statistical comparison. CONCLUSION: Together, the investigated combination is tolerable and feasible. Neither the addition of PEG-Dox nor the prolonged administration of Temozolomide resulted in a meaningful improvement of the patient's outcome as compared to the EORTC26981/NCIC-CE.3 data.